QAM
SMMT icon

Q3 Asset Management’s Summit Therapeutics SMMT Stock Holding History

Q3 Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290K Hold
19,950
– – 0.05% 66
2026
Q1 		$378K Buy
19,950
+383
+2% +$6.19K 0.09% 60
2025
Q4 		$342K Hold
19,567
– – 0.08% 57
2025
Q3 		$404K Hold
19,567
– – 0.14% 46
2025
Q2 		$416K Buy
19,567
+3,094
+19% +$70.6K 0.15% 39
2025
Q1 		$317K Hold
16,473
– – 0.22% 41
2024
Q4 		$293K Hold
16,473
– – 0.18% 45
2024
Q3 		$360K Buy
+16,473
New +$230K 0.08% 42
2023
Q2 		– Sell
-15,761
Closed -$27K – 65
2023
Q1 		$27K Buy
+15,761
New +$43K 0.02% 43

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Q3 Asset Management's SMMT Position: Q2 2026 in Review

Q3 Asset Management held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 19,950 shares worth $290K. The position accounts for 0.05% of the portfolio, ranked #66.

Q3 Asset Management first reported a position in SMMT in Q1 2023 and has held it in 9 quarters since. The position peaked at $416K in Q2 2025. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Q3 Asset Management held 19,950 shares of Summit Therapeutics worth $290K as of Q2 2026.
  • Q3 Asset Management left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up 0.05% of Q3 Asset Management's portfolio in Q2 2026, its #66 holding.
  • Q3 Asset Management first reported a position in Summit Therapeutics in Q1 2023 and has held it in 9 quarters since.
  • Q3 Asset Management's Summit Therapeutics position peaked at $416K in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Q3 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.